Anaplastic thyroid cancer therapy: Dream or reality?

Endocrine

Volumn 42, Issue 3, 2012, Pages 468-470

  Elisei, Rossella ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; AURORA KINASE INHIBITOR; BARASERTIB; BORTEZOMIB; CISPLATIN; COMBRETASTATIN A4; MEVINOLIN; PACLITAXEL; PROTEASOME INHIBITOR; RADIOACTIVE IODINE; SORAFENIB; TOZASERTIB;

ANAPLASTIC THYROID CANCER; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER GENE THERAPY; CANCER INHIBITION; CANCER THERAPY; DISTANT METASTASIS; EDITORIAL; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; SURVIVAL TIME; THYROID CARCINOMA; THYROIDECTOMY; CARCINOMA; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; THYROID TUMOR;

CARCINOMA; HUMANS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 84878234366     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9785-x     Document Type: Editorial

References (11)

1. S.M. Lim, S.J. Shin, W.Y. Chung, C.S. Park, K.H. Nam, S.W. Kang, K.C. Keum, J.H. Kim, J.Y. Cho, Y.K. Hong, B.C. Cho, Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med. J. 53(2), 352-357 (2012)
2. A. Wunderlich, S. Roth, A. Ramaswamy, B.H. Greene, C. Brendel, U. Hinterseher, D.K. Bartsch, S. Hoffmann, Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer. Endocrine (2012). doi: 10.1007/s12020-012-9665-4
3. A. Wunderlich, T. Arndt, M. Fischer, S. Roth, A. Ramaswamy, B.H. Greene, C. Brendel, U. Hinterseher, D.K. Bartsch, S. Hoffmann, Targeting the proteasome as a promising therapeutic strategy in thyroid cancer. J. Surg. Oncol. 105(4), 357-364 (2012)
4. Y. Arlot-Bonnemains, E. Baldini, B. Martin, J.G. Delcros, M. Toller, F. Curcio, F.S. Ambesi-Impiombato, M. D'Armiento, S. Ulisse, Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr. Relat. Cancer 15(2), 559-568 (2008)
5. S. Libertini, A. Abagnale, C. Passaro, G. Botta, S. Barbato, P. Chieffi, G. Portella, AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr. Relat. Cancer 18(1), 129-141 (2011)
6. A. Antonelli, G. Bocci, C. La Motta, S.M. Ferrari, P. Fallahi, I. Ruffilli, A. Di Domenicantonio, A. Fioravanti, S. Sartini, M. Minuto, S. Piaggi, A. Corti, G. Ali, T. Di Desidero, P. Berti, G. Fontanini, R. Danesi, F. Da Settimo, P. Miccoli, CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J. Clin. Endocrinol. Metab. 97(4), E528-E536 (2012)
7. W.B. Zhong, S.P. Hsu, P.Y. Ho, Y.C. Liang, T.C. Chang, W.S. Lee, Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway. Biochem. Pharmacol. 82(11), 1663-1672 (2011)
8. S. Gholami, D. Haddad, C.H. Chen, N.G. Chen, Q. Zhang, P.B. Zanzonico, A.A. Szalay, Y. Fong, Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter. Surgery 150(6), 1040-1047 (2011)
9. R. Elisei, A. Vivaldi, R. Ciampi, P. Faviana, F. Basolo, F. Santini, C. Traino, F. Pacini, A. Pinchera, Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J. Clin. Endocrinol. Metab. 91(6), 2389-2395 (2006)
10. R. Elisei, J. Sosa, B. Jarzab et al., Randomized phase 2/3 trial of a tumor vascular disrupting agent fosbretabulin (CA4P) with carboplatin and paclitaxel in anaplastic thyroid cancer (ATC). ITC Abstract Book (2010)
11. V. Gupta-Abramson, A.B. Troxel, A. Nellore, K. Puttaswamy, M. Redlinger, K. Ransone, S.J. Mandel, K.T. Flaherty, L.A. Loevner, P.J. O'Dwyer, M.S. Brose, Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 26(29), 4714-4719 (2008)